Evidence map›Paper›PMID 16996084›Full record

ArticleJournal of molecular biology2006

New peptide inhibitors of type IB topoisomerases: similarities and differences vis-a-vis inhibitors of tyrosine recombinases.

David F Fujimoto, Clemencia Pinilla, Anca M Segall

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of molecular biology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

David F FujimotoDepartment of Biology, Center for Microbial Sciences and Molecular Biology Institute, San Diego State University, San Diego, CA 92182-4614, USA.
Clemencia Pinilla
Anca M Segall
San Diego State University · USTorrey Pines Institute For Molecular Studies · US

Funding

PATHWAYS OF LAMBDA SITE SPECIFIC RECOMBINATIONR01GM052847 · NIGMS · SAN DIEGO STATE UNIVERSITY · PI SEGALL, ANCA MARA · 1996 to 2010
$2.4M
Inhibitors of pox virus Holliday juction resolvaseR21AI061351 · NIAID · SAN DIEGO STATE UNIVERSITY · PI SEGALL, ANCA MARA · 2004 to 2005
$604k
NIAID NIH HHS R21 AI061351NIGMS NIH HHS R01 GM052847PHS HHS 2R01 52847PHS HHS F32 65685PHS HHS R21 61351
6 · The paper itself

Abstract

Topoisomerases relieve topological tension in DNA by breaking and rejoining DNA phosphodiester bonds. Type IB topoisomerases such as vaccinia topoisomerase (vTopo) and human topoisomerase I are structurally and mechanistically similar to the tyrosine recombinase family of enzymes, which includes bacteriophage lambda Integrase (Int). Previously, our laboratory identified peptide inhibitors of Int from a synthetic peptide combinatorial library. The most potent of these peptides also inhibit vTopo. Here, we used the same mixture-based screening procedure to identify peptide inhibitors directly against vTopo using a plasmid relaxation assay. The two most potent new peptides identified, WYCRCK and KCCRCK, inhibit plasmid relaxation, DNA cleavage and Holliday junction (HJ) resolution mediated by vTopo. The peptides tested bind double-stranded DNA at high concentrations but do not appear to displace the enzyme from its DNA substrate. WYCRCK binds specifically to HJ and perturbs the central base-pairing. This peptide also accumulates HJ intermediates when it inhibits Int-mediated recombination, whereas KCCRCK does not. Interestingly, WYCRCK shares four amino acids with a peptide identified against Int, WRWYCR. The octapeptide WRWYCRCK, containing amino acids from both hexapeptides, is more potent than either against vTopo. All peptides are less potent against the type IA Escherichia coli topoisomerase I or against restriction endonucleases. Like the Int-inhibitory peptide WRWYCR, WYCRCK binds to HJs, and both inhibit junction resolution by vTopo. Our results suggest that the newly identified WYCRCK and peptide WRWYCR interact with a distorted DNA intermediate arising during vTopo-mediated catalysis, or interfere with specific interactions between vTopo and DNA.

Indexed as

Topoisomerase I InhibitorsBacteriophage lambdaDNADNA, CruciformDNA Restriction EnzymesDNA Topoisomerases, Type IEscherichia coliHumansIntegrase InhibitorsIntegrasesOligopeptidesRecombination, GeneticTyrosineVaccinia virusDNADNA, CruciformDNA Restriction EnzymesDNA Topoisomerases, Type IIntegrase InhibitorsIntegraseslysyl-cysteinyl-cysteinyl-arginyl-cysteinyl-lysineOligopeptidesTopoisomerase I Inhibitorstryptophyl-tyrosyl-cysteinyl-arginyl-cysteinyl-lysineTyrosine

Identifiers

PMID16996084
PMCPMC1876744
OpenAlexW2134754270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.